525 related articles for article (PubMed ID: 22335615)
21. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
Kiratisin P; Keel RA; Nicolau DP
Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484
[TBL] [Abstract][Full Text] [Related]
22.
Flamm RK; Shortridge D; Castanheira M; Sader HS; Pfaller MA
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427295
[TBL] [Abstract][Full Text] [Related]
23. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
[TBL] [Abstract][Full Text] [Related]
24. Nationwide surveillance of antimicrobial resistance among clinically important Gram-negative bacteria, with an emphasis on carbapenems and colistin: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2018.
Lee YL; Lu MC; Shao PL; Lu PL; Chen YH; Cheng SH; Ko WC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Lee WS; Shi ZY; Chen YS; Wang FD; Tseng SH; Lin CN; Chen YH; Sheng WH; Lee CM; Liao MH; Hsueh PR
Int J Antimicrob Agents; 2019 Sep; 54(3):318-328. PubMed ID: 31202925
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
26. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265
[TBL] [Abstract][Full Text] [Related]
27. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
Song JY; Kee SY; Hwang IS; Seo YB; Jeong HW; Kim WJ; Cheong HJ
J Antimicrob Chemother; 2007 Aug; 60(2):317-22. PubMed ID: 17540672
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
Pillar CM; Torres MK; Brown NP; Shah D; Sahm DF
Antimicrob Agents Chemother; 2008 Dec; 52(12):4388-99. PubMed ID: 18779357
[TBL] [Abstract][Full Text] [Related]
29. In vitro activities of 'new' and 'conventional' antibiotics against multi-drug resistant Gram negative bacteria from patients in the intensive care unit.
Ratnam I; Franklin C; Spelman DW
Pathology; 2007 Dec; 39(6):586-8. PubMed ID: 18027263
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial Susceptibility among European Gram-Negative and Gram-Positive Isolates Collected as Part of the Tigecycline Evaluation and Surveillance Trial (2004-2014).
Rodloff AC; Dowzicky MJ
Chemotherapy; 2017; 62(1):1-11. PubMed ID: 27216271
[TBL] [Abstract][Full Text] [Related]
31. Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs.
Mezzatesta ML; Caio C; Gona F; Cormaci R; Salerno I; Zingali T; Denaro C; Gennaro M; Quattrone C; Stefani S
Int J Antimicrob Agents; 2014 Aug; 44(2):112-6. PubMed ID: 25059444
[TBL] [Abstract][Full Text] [Related]
32. Treatment and Outcome of Carbapenem-Resistant Gram-Negative Bacilli Blood-Stream Infections in a Tertiary Care Hospital.
Shah PG; Shah SR
J Assoc Physicians India; 2015 Jul; 63(7):14-8. PubMed ID: 26731822
[TBL] [Abstract][Full Text] [Related]
33. Global assessment of antimicrobial susceptibility among Gram-negative organisms collected from pediatric patients between 2004 and 2012: results from the Tigecycline Evaluation and Surveillance Trial.
Kehl SC; Dowzicky MJ
J Clin Microbiol; 2015 Apr; 53(4):1286-93. PubMed ID: 25653413
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of tigecycline and comparators against gram-negative bacteria isolated from a tertiary hospital in Alexandria, Egypt.
Mohamed NM; Youssef AA
Microb Drug Resist; 2011 Dec; 17(4):489-95. PubMed ID: 21875338
[TBL] [Abstract][Full Text] [Related]
35. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
[TBL] [Abstract][Full Text] [Related]
36. In Vitro Analysis of Activities of 16 Antimicrobial Agents against Gram-Negative Bacteria from Six Teaching Hospitals in China.
Chen H; Wang Z; Li H; Wang Q; Zhao C; He W; Wang X; Zhang F; Wang H
Jpn J Infect Dis; 2015; 68(4):263-7. PubMed ID: 25672407
[TBL] [Abstract][Full Text] [Related]
37. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.
Bertrand X; Dowzicky MJ
Clin Ther; 2012 Jan; 34(1):124-37. PubMed ID: 22154196
[TBL] [Abstract][Full Text] [Related]
38. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06.
Livermore DM; Hope R; Brick G; Lillie M; Reynolds R;
J Antimicrob Chemother; 2008 Nov; 62 Suppl 2():ii55-63. PubMed ID: 18819980
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian study.
Gales AC; Azevedo HD; Cereda RF; Girardello R; Xavier DE;
Braz J Infect Dis; 2011; 15(6):513-20. PubMed ID: 22218508
[TBL] [Abstract][Full Text] [Related]
40. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
